Lv4
540 积分 2022-11-24 加入
Ziftomenib: First Approval
1个月前
已完结
Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia
1个月前
已完结
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
1个月前
已完结
Next generation epigenetic modulators to target myeloid neoplasms
1个月前
已完结
Revumenib for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation
1个月前
已完结
Revumenib: First Approval
1个月前
已完结
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
1个月前
已完结
MEN1 mutations mediate clinical resistance to menin inhibition
1个月前
已完结
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
1个月前
已完结
Proteolysis-targeting chimeras with reduced off-targets
1个月前
已完结
皖公网安备34019202002308
